L'intérêt à découvert pour Sobr Safe donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Sobr Safe. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Sobr Safe (NASDAQ:SOBR) Stock, Rapport sur les intérêts à découvert

Sobr Safe

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending SOBRsafe software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

Sobr Safe Inc

News

Contracts

MRAM

Everspin Awarded $10.5M Contract For MRAM IP And Foundry Services For Purdue University's ME Commons In-Memory Compute Project

<p>Baird  analyst Shrenik Kothari   maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $240 to $250.</p>


Price Target

Analyst Ratings

Baird Maintains Outperform on Zscaler, Raises Price Target to $250

Earnings

Earnings Beats

Earnings Misses

VYNE

VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate

<p>Baird  analyst Joe Vruwink   maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $283 to $285.</p>


VEEV

Baird Maintains Outperform on Veeva Systems, Raises Price Target to $285

ALLR

Allarity Therapeutics Announces ITs Phase 2 Trial Of Stenoparib In Combination With Temozolomide For Recurrent Small Cell Lung Cancer, Being Fully Funded By US Veterans Administration

<p>Baird  analyst William Power   maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Outperform and lowers the price target from $390 to $300.</p>


Baird Maintains Outperform on MongoDB, Lowers Price Target to $300

Curtiss-Wright Receives $18M Follow-On Order From US Marine Corps

<p>No gainer in today's Pre-market session. </p>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">217.58</td>
<td align="right">-3.99</td>
<td align="right">-1.81</td>
<td>19.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">49.70</td>
<td align="right">-0.51</td>
<td align="right">-1.02</td>
<td>255.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">209.31</td>
<td align="right">-2.10</td>
<td align="right">-1.00</td>
<td>364</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.95</td>
<td align="right">-0.54</td>
<td align="right">-0.70</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">148.93</td>
<td align="right">-0.75</td>
<td align="right">-0.51</td>
<td>4.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.20</td>
<td align="right">-0.22</td>
<td align="right">-0.51</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.06</td>
<td align="right">-0.38</td>
<td align="right">-0.47</td>
<td>1.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.34</td>
<td align="right">-0.36</td>
<td align="right">-0.43</td>
<td>13.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.84</td>
<td align="right">-0.20</td>
<td align="right">-0.23</td>
<td>326</td>
</tr>
</tbody>
</table>
<p><a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. </p>
<p><em>To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.</em> </p>


Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For March 6, 2025

WIIM

TSLA

Tesla shares are trading lower after Baird lowered its price target on the stock from $440 to $370.

<p>Baird  analyst Craig Kennison   maintains Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) with a Outperform and lowers the price target from $110 to $100.</p>


Baird Maintains Outperform on Thor Industries, Lowers Price Target to $100

BECN

Beacon Acquires DM Figley, Terms Not Disclosed

CNTM

ConnectM Secured Over 5,500 Orders For MELI Mobility Edge And AURAI Platform Subscriptions From Existing OEM Customers In First Two Months Of 2025

<p>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.27) by 37.8 percent. This is a 1.25 percent increase over losses of $(0.80) per share from the same period last year.  The company reported quarterly sales of $29.66 million which beat the analyst consensus estimate of $24.91 million by 19.09 percent.  This is a 4.25K percent increase over sales of $682.00 thousand the same period last year.</p>


PHAT

Phathom Pharmaceuticals Q4 Adj $(0.79) Beats $(1.27) Estimate, Sales $29.66M Beat $24.91M Estimate

<p>Baird  analyst Jonathan Komp   maintains Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Neutral and lowers the price target from $24 to $20.</p>


Baird Maintains Neutral on Foot Locker, Lowers Price Target to $20

<p>Baird  analyst Ben Kallo   maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and lowers the price target from $440 to $370.</p>


Baird Maintains Outperform on Tesla, Lowers Price Target to $370

LFMD

LifeMD Announces Integration With LillyDirect Pharmacy Provider Gifthealth To Offer Access To Branded Dual GLP-1/GIP Zepbound

<p>Needham  analyst Charles Shi   reiterates Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and maintains $19 price target.</p>


Reiteration

SVCO

Needham Reiterates Buy on Silvaco Group, Maintains $19 Price Target

<p>Needham  analyst John Todaro   maintains CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Buy and lowers the price target from $16 to $15.</p>


CMPO

Needham Maintains Buy on CompoSecure, Lowers Price Target to $15

<ul>
<li>Adjusted EBITDA of $210 million to $220 million (vs. previous outlook of $200 million to $215 million)</li>
</ul>


Guidance

CBRL

Cracker Barrel Revises FY25 Total Revenue Outlook From $3.4B - $3.5B To $3.45B - $3.50B, Est $3.46B

General

BURU

COEP

NUBURU Announces Partnership With COEPTIS' NexGenAI Affiliates Network

Offerings

Press Releases

SOBRsafe Announces Pricing of $8.2 Million Private Placement

SOBRsafe Announces Closing of $8.2 Million Private Placement

Aegis Capital Corp. acted as Exclusive Placement Agent on an $8.2 Million Private Placement for SOBR Safe, Inc. (NASDAQ:SOBR)

SOBRsafe Launches Revolutionary Alcohol Detection Software: Transforming Patient Care for Behavioral Health Providers

SOBRsafe Regains Compliance with Nasdaq Listing Requirements

SOBRsafe Releases Real-Time Alcohol Detection Wristband with Premium Updates

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

"Peraso Inc. (NASDAQ: PRSO) Ignites the 60 GHz mmWave Revolution-Powering AI, Defense, and 5G with Cutting-Edge Semiconductor Innovation – More Stocks Inside"

Emerging Market Disruptors: PNPN.V, SOBR, EFOI, HCTI, PRSO, High-Growth Stocks Shaping the Future of AI, Defense, 5G, and Energy Metals

Small Cap

SOBRsafe and Orbiit Announce Partnership to Enhance Alcohol Recovery Through AI and Wearable Technology

Comments

Sobr Safe

Intérêt court

Sobr Safe (NASDAQ:SOBR) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL